Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial

Bug, G., Burchert, A., Wagner, E. M., Kroeger, N., Jedlickova, Z., Gueller, S., Wolf, A., Huenecke, S., Bader, P., Serve, H. and Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330 2015. Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial. Bone Marrow Transplantation 50 , S59-S59. 10.1038/bmt.2015.27

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Nature Publishing Group
ISSN:	0268-3369
Last Modified:	02 Nov 2022 09:54
URI:	https://orca.cardiff.ac.uk/id/eprint/96780

Actions (repository staff only)

Edit Item